MRUSPhase 2 Readout
Combination cohort clinical update
Merus | Petosemtamab | Head and neck cancer
Catalyst details
Clinical trial completion and company event watch item.
Phase
Phase 2
Expected date
2026-10-01
Expected period
Q4 2026
Source type
manual
quarterupcoming
Source URLNotes
This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.
Open company detailHistory of changes
No sample changes for this catalyst.